Abstract Admission hyperglycemia impacts ischemic stroke deleteriously, but the relative role of acute hyperglycemia (HG) vs diabetes in the pathogenesis of this poor outcome is not clear. The study aims to determine the effect of acute HG on neurovascular outcomes of stroke under control and diabetic conditions. Moderate acute HG (140-200 mg/dl) was achieved by glucose injection before middle cerebral artery occlusion (MCAO) in control Wistar and diabetic GotoKakizaki rats. Following 3 h MCAO/21 h reperfusion, we measured infarct size, hemorrhagic transformation (HT) frequency, excess hemoglobin, neurobehavioral outcome, and MCA matrix metalloprotease activity. Infarct size was significantly smaller in diabetic rats. Moderate acute HG increased neuronal damage in diabetic but not in control rats. HT frequency and hemoglobin were significantly higher in diabetic rats. HG augmented vascular damage in control rats and had no additional effect on bleeding in diabetic rats. Neurological deficit was greater in diabetic rats and was worsened by HG. The finding that functional outcome is poorer in both acute HG and diabetes without a significant increase in infarct size suggests that amplified vascular damage contributes to neurological deficit in hyperglycemia. These results highlight the importance of vascular protection to improve neurological outcome in acute ischemic stroke.
Introduction
Ischemic stroke is a leading cause of death and disability in the USA, and diabetes is the most rapidly increasing risk factor for stroke [1] . Stroke risk in patients with diabetes is 2-6-folds higher than age-matched controls [1] . The shortand long-term functional outcomes are worse, and mortality is greater in stroke patients with diabetes as compared to the non-diabetic population [2] . In addition to increased risk for stroke with diabetes, acute hyperglycemia (HG), which can develop as a stress response, exacerbates stroke [3] [4] [5] . However, it is not clear whether there is a difference between the effects of HG vs diabetes on clinical stroke outcomes [6] . This is clinically important as the current stroke guidelines emphasize the need for randomized controlled trials to determine best practice for managing hyperglycemia [7] . The UK Glucose Insulin in Stroke Trial randomized clinical trial [8] enrolled predominantly patients without diabetes (83%). Although insulin achieved target blood glucose levels, there was no difference in stroke outcomes. Results from THIS [9] and GRASP [10] pilot trials, both of which enrolled mainly diabetic patients (>50%), have suggested a favorable outcome in patients rapidly treated for hyperglycemia. While needing confirmation by larger trials, these results highlight the importance of targeting the right patient populations and the right blood glucose range to be achieved clinically.
Previous preclinical studies on diabetic and hyperglycemic ischemic brain injury do not provide sufficient information as most studies employed HG induced by either glucose injection or streptozotocin (STZ) injection 2 to 3 days prior to stroke with very high blood glucose levels [11] [12] [13] . However, recent clinical evidence suggests that blood glucose levels in stroke patients that present with hyperglycemia at admission range between 140 and 200 mg/dl [6, 9, 14] . Understanding the mechanisms behind diabetes vs HG-dependent stroke pathology in animal models that closely represent the clinical condition is paramount in improving current preventive and therapeutic interventions.
The Goto-Kakizaki (GK) model is a lean yet insulin resistant model of type 2 diabetes which spontaneously develops non-insulin-dependent diabetes around 6 weeks of age [15, 16] . GK diabetic rats are a progeny of selectively inbred Wistar animals over multiple generations using glucose intolerance as a selection marker and as such Wistar rats serve as a control of the same genetic background. We chose this model since the level of hyperglycemia is moderate (∼180 mg/dl) and animals do not have confounding factors such as dyslipidemia or hypertension which allows us to study the impact of moderate changes in blood glucose and insulin resistance on cerebrovascular complications of diabetes.
Matrix metalloproteases (MMP) play an important role in vascular remodeling as well as stroke pathophysiology [17] [18] [19] . We previously reported that augmented cerebrovascular MMP-2 and MMP-9 activity in the GK model of type-2 diabetes is associated with enhanced remodeling [20] and increased hemorrhagic transformation (HT) following ischemic stroke [21] . Our most recent findings showed that glycemic control or inhibition of MMPs by minocycline prevents cerebrovascular remodeling, reduces HT, and improves outcomes [22] . However, cerebrovascular MMP-9 levels in acute hyperglycemia and relation to stroke pathology remain unknown.
Building upon these past findings, this study was designed to address the questions: (1) How do moderate acute hyperglycemia and diabetes affect neurovascular damage and stroke outcome?, (2) does a further acute elevation in blood glucose at the time of ischemia exacerbate neuronal and vascular injury in diabetes?, and (3) how do HG and diabetes influence vascular MMP-9 following ischemic stroke?
Materials and Methods

Animal Models
The institutional animal care and use committees of the Medical College of Georgia and the Charlie Norwood Veterans Affairs approved all protocols. Male Wistar and GK rats were from Harlan (Indianapolis, IN, USA) and Taconic (Hudson, NY, USA), respectively, and weighed (260-310 g). Study groups included (1) control, (2) control + acute HG, (3) diabetes, and (4) diabetes + acute HG. Acute HG was achieved by a 3-ml IP glucose injection (300 mmol) 20-30 min before middle cerebral artery occlusion (MCAO) and was maintained during ischemia by another injection 1.5 h after MCAO. Two additional groups were (1) diabetic rats treated with metformin (300 mg/kg/day) starting at the onset of diabetes till MCAO and (2) diabetic rats treated with metformin and given acute HG during MCAO. The purpose of the last two groups was to determine (1) whether glycemic control prevents/reduces injury if a stroke is superimposed on diabetes and (2) whether an acute elevation in blood glucose causes the same damage if there was prior glycemic control in diabetes. Metformin was given in drinking water artificially sweetened by non-caloric sweetener for the 4 weeks before the study. Blood glucose was measured from tail vein using a glucometer (Freestyle, Alameda, CA, USA) and reported at baseline, MCAO surgery, and sacrifice. MCAO blood glucose levels were given as the average of readings at induction of anesthesia and 1 h MCAO.
Experimental Temporary Focal Cerebral Ischemia
Three hours of MCAO was performed under 3% isoflurane anesthesia followed by 21 h reperfusion using a modified Longa method as we reported before [21] while animals were being ventilated on anesthesia machine. A midline cervical incision was made to expose the common carotid artery. The external carotid artery separated, ligated, and severed. A rounded-tip, by heating, 4-0 nylon monofilament suture was inserted into the internal carotid artery to occlude the origin of MCA [23] . The occlusion suture was secured with one-silk suture at the stump of external carotid artery, and the incision was closed. After 3 h, the animals were reanesthetized, and the occlusion suture was removed to allow reperfusion. Scanning laser Doppler (Pim-3, Perimed, ST) was used to confirm a similar degree of drop in flow between groups by measuring MCAO perfusion levels compared to baseline following scalp incision [24] . Core body temperature was monitored rectally during MCAO, and then core temperature was maintained using a heating pad under the animal and under the cage till the end of 24 h. Animals were singly housed before and after MCAO with free access to food and water. In a subset of animals, arterial blood gases were measured before and after MCAO as well as postreperfusion via femoral artery catheterization.
Evaluation of Neurovascular Injury
Neurovascular injury in this study refers to infarct size (neuronal injury) and HT and edema (vascular injury). Before sacrifice animals underwent intracardiac perfusion of ice-cold saline to flush blood from the vessels. Brains were extracted and MCAs were isolated from ischemic and nonischemic hemispheres. Visual inspection of hemorrhage was done, documented per slice if present, and reported in a binary fashion as yes or no to indicate the frequency of macroscopic bleeding. 2,3,5-Triphenyltetrazolium chloride (TTC) was used on the same set of animals afterward to outline the infarct area. Following staining, images of the above brains were analyzed in a blinded fashion using Image-J. Edema is reported as the percent increase in ischemic hemisphere size to the contralateral hemisphere. Infarct volume is reported as the percentage of infarcted area of ipsilateral hemisphere corrected for edema. Indirect infarct size was also calculated as contralateral area minus the area of noninfarcted tissue in the ischemic hemisphere. Following image capturing, hemispheres were separated and stored at −80°C for later hemoglobin (Hb) ELISA. HT was quantified by measuring excess Hb in the stroked hemisphere compared to the contralateral side as previously published [25] .
Evaluation of MMP Activity
MCAs isolated from ischemic and nonischemic hemispheres were homogenized as reported previously [20] , and 30 μg homogenate was assayed by gelatin zymography as we reported previously [21] . Briefly, samples were loaded directly on SDS-PAGE gel containing 0.1% gelatin and separated under non-reducing conditions. Following electrophoresis, the gel was washed twice in 2.5% "Triton X100" for 20 min each, rinsed with ddH 2 O, and incubated for 20 h in a substrate buffer "50 mmol Tris-HCl, 5 mmol CaCl 2 +0.02% NaN 3 , pH=7.5" at 37°C. Recombinant MMP-9 active standard was run as positive control (Calbiochem, catalogue# PF024). Following incubation, the gel was stained using "Coomassie blue" for 3 h then destained. The zymogram was digitized and band intensity was quantified by image analysis "GelPro analyzer, Media Cybernetics, MD" and expressed as the percentage of the recombinant standard.
Evaluation of Neurological Outcome
Ipsilateral circling, paw grasp, and beam walk tests assessed function at baseline, before MCAO and at 24 h. Scores were graded 0-3 (normal-maximum deficit): ipsilateral circling (no/few/several and continuous circling), paw grasp (normal grasp/stroke side can touch/stroke side hard to touch and unable to touch), and beam walk (animal readily traverses/walks slowly and shaking/can stay or eventually falls and unable to stay for 10 s). A total score of 9 indicated the worst outcome. Bederson's score was recorded at baseline and after occlusion to verify proper occlusion [26] .
Statistics
The distributions for the measures of stroke severity (infarct size, percent edema, and bleeding) as well as the measures of behavior were found to be skewed. A rank transformation was used prior to the analysis of these measures. The analysis for the effect of hyperglycemia on Wistar and GK rats was performed using a 2 disease (Wistar vs GK)×2 treatment (vehicle vs hyperglycemia) ANOVA. An interaction between disease and treatment would indicate a differential effect of inducing hyperglycemia that is dependent on disease status. The analysis for the effects of hyperglycemia and metformin was performed using a 2 hyperglycemia (no vs yes)×2 metformin (no vs yes) factorial ANOVA. An interaction between hyperglycemia and metformin would indicate a differential effect of metformin treatment dependent on hyperglycemic status. A Tukey's test was used to adjust for multiple comparisons when determining mean differences for significant interactions. Results are reported as mean±SEM.
Results
Physiological Parameters
Blood glucose levels over the course of MCAO/reperfusion are depicted in Fig. 1a . During ischemia, we achieved (1) a blood glucose range in control rats similar to the average blood glucose values in diabetic GK rats (140-200 mg/dl) and (2) an acute increase in blood glucose in diabetic rats. Baseline blood glucose was significantly higher in diabetic than in control rats. In all groups, blood glucose increased during MCAO and diabetic rats showed a greater elevation in blood glucose compared to control + HG group (Fig. 1a) . The purpose of the second glucose IP injection midway during occlusion was to maintain HG during MCAO. At sacrifice, blood glucose dropped to similar level in all groups. Metformin corrected hyperglycemia in diabetic rats. Glucose injection achieved a similar degree of increase in blood glucose in both vehicle-and metformin-treated diabetic rats at baseline (Fig. 1b) . At sacrifice, blood glucose dropped to control levels in all groups (Fig. 1a) . Arterial blood gases measurements were similar between control and diabetic rats before and after MCAO as well as postreperfusion (Table 1) .
Neurovascular Damage
Infarct size was significantly lower in diabetic rats than in controls as we previously reported (Fig. 2a, b) [21] . Indirect infarct size measurements showed similar results (not shown). There was a disease and treatment interaction such that HG increased infarct size in diabetic (30% vs 10%) but not in control (30%; Fig. 2b ). Metformin pretreatment did not affect infarct size in diabetic rats with or without additional acute HG (Fig. 2b) . The percent reduction in blood flow from baseline after MCAO was similar in all groups indicating consistent occlusion (Fig. 2c) .
Edema and HT were analyzed as indices of vascular damage. HT was assessed qualitatively by observing macroscopic hemorrhagic transformation and quantitatively by Hb ELISA (nanograms per milligram protein; Fig. 3b, c) . Diabetic rats had a higher rate of HT than the controls (87% vs 15%, p<0.001). Excess Hb and edema were higher in diabetes indicating vascular damage, and there was a disease and treatment interaction such that HG increased both (Fig. 3c, d ).
Metformin reduced brain edema in diabetic rats (Fig. 3d) . While it did not affect the rate of HT, bleeding severity was reduced (Fig. 3c) .
MMP Activity
MMP-9 is associated with disruption of vascular integrity in ischemic stroke. MCA MMP-9 activity was measured (Fig. 4) . MCA MMP-9 activity was greater in the nonischemic hemisphere of diabetic rats than in control. Ischemia enhanced MCA MMP-9 activity in both control and diabetic rats. Metformin pretreatment did not affect MMP-9 activity on the nonischemic side but prevented the increase on the ischemic hemisphere. HG did not change MCA MMP-9 activity.
Neurological Outcome
Short-term (24-h) outcomes were assessed. Neurological deficits were more pronounced in diabetes rats, and HG worsened functional outcomes in both control and diabetic rats (Fig. 5) . Metformin improved the deficit in diabetic animals.
Discussion
This study provides several important lines of evidence on the effects of acute hyperglycemia and diabetes (chronic hyperglycemia) on neurovascular and functional outcomes Fig. 4 Local MCA MMP-9 activity under basal and ischemic conditions. MCA MMP-9 lytic of non-stroke (NS) and stroke (S) hemispheres by gelatin zymography. Baseline (NS) activity was greater in diabetes than in control and further increased with ischemia. *p<0.05 vs NS, **p<0.001 vs C S, and ***p<0.001 vs D S of stroke: (1) moderate acute hyperglycemia amplifies vascular damage (edema and HT) without increasing infarct size following stroke in otherwise healthy rats. (2) Moderate diabetes is associated with smaller infarcts but greater edema and HT. Overlaying acute hyperglycemia in diabetes exacerbates infarction but does not amplify the HT or edema that is already greater in diabetic rats compared to control rats. (3) To the best of our knowledge, this is the first study that reports acute hyperglycemia effects on stroke outcomes in an insulin resistant diabetes model which is clinically very important. (4) Upregulation of macrovascular MMP-9 activity contributes to increased vascular damage in diabetes but not in acute hyperglycemia. (5) Glycemic control provides vascular protection in diabetes. The interesting finding that functional outcomes are worse in acute hyperglycemic and diabetic rats despite relatively smaller infarcts strongly suggests that vascular injury contributes to the neurological deficits. Diabetes and HG are predictors of poor ischemic stroke outcomes. Yet, limited knowledge exists about the different pathophysiology, outcomes, and the mechanisms of injury in each case [6, 27] . Clinical findings link admission HG independent of diabetes to poor outcomes and to increased odds of HT [28, 29] . Therefore, we rely on preclinical studies to better understand the effects of hyperglycemia on stroke injury. However, as recently reported in a metaanalysis on the hyperglycemia and infarct size in animal models of stroke [30] , results are conflicting. In general, larger infarct size and higher mortality rates were reported after hyperglycemic ischemic stroke. These studies employed acutely induced severe hyperglycemia [31, 32] , and severe HG (∼500 mg/dl) was induced acutely prior to MCAO using STZ [11] . The need for studies with relevant hyperglycemia models was highlighted in a recent review [30] . Our study expands our current knowledge as we studied glucose levels that closely resemble the clinical situation where admission hyperglycemia is defined as glycemia >140 mg/dl [6, 9, 14] . Furthermore, acute hyperglycemia was induced in both normal and previously diabetic rats which allows us to study the interaction of acute hyperglycemia and type-2 diabetes on stroke injury. Earlier studies reported that acute elevations induced by glucose injection caused a drop in cerebral blood flow due to an osmotic effect which may be a factor in worsened outcomes [33] [34] [35] . While we cannot completely rule out this possibility, in the current study, since the target blood glucose range was 140-200 mg/dl, only a small volume was injected. Moreover, we routinely monitored cerebral blood flow with scanning laser Doppler before and after occlusion and did not detect a difference between control and control + HG animals.
The infarct size in our diabetic rats was smaller than control as we previously reported [21, 36, 37] . This may be due to diabetes-mediated stimulation of survival mechanisms as a compensatory response early in the disease process [38] . We had hypothesized that if diabetes activates survival pathways in GK rats, then glucose control would prevent this effect and GKs would develop infarct sizes similar to control. However, there was no significant change in infarct size due to metformin pretreatment. This would suggest that the smaller infarcts in GK are either not due to diabetes-mediated changes in cell survival or that this is a metformin-specific protective effect. Recent studies reported that metformin may also be neuroprotective [39, 40] . Future studies are needed to address the preconditioning possibility in GK rats in more depth. At the levels of acute hyperglycemia achieved in our study, ischemic damage in control HG rats was not different from control normoglycemic animals. Yet, when acute HG was superimposed on diabetic rats, ischemic damage increased. This finding may be due to the fact that while baseline blood glucose was similar between control + HG and diabetes groups at the beginning of stroke surgery, diabetic animals showed a greater spike during MCAO indicating a greater stress response. While the reasons are not completely delineated, acute HG in human stroke may be due to stress response by activation of the sympathetic system or the hypothalamicpituitary-adrenal axis. In our model, acute HG was induced by glucose injection, but the role(s) of these systems cannot be excluded in our findings.
Neurovascular unit integrity is compromised following prolonged ischemia causing edema and HT due to disruption of the tight junction proteins and vessel breakdown. Admission blood glucose is a predictor of HT in patients given tissue plasminogen activator (t-PA) [3] [4] [5] . Thus, controlling HG in ischemic stroke is likely to be important in maximizing the potential of reperfusion therapy with t-PA. Our previous studies in GK rats showed that HT does not occur if MCA is occluded permanently providing evidence that HT is an indicator of reperfusion injury [36] . Since we were interested in vascular injury and HT, the current study employed a reversible occlusion model with longer (3 h) duration of occlusion which reproducibly causes HT as we have previously shown. This time frame also falls within the therapeutic window t-PA has to be administered to a stroke patient. In our study, 87% of diabetic rats exhibited intracerebral bleeding while this was 100% in HG animals vs 15% in control. Upon quantification, severity of HT was higher in diabetic rats compared to control. Edema was higher in diabetic and HG rats compared to control, suggesting that cerebrovasculature is susceptible to damage by hyperglycemia regardless of diabetes. More sensitive methods for measuring edema could confirm these finding in future studies. It also points out that the threshold for vascular damage is relatively low and mild-moderate levels of HG are sufficient to induce it. Another explanation may be that 3 h occlusion is too severe and these studies need to be repeated with a shorter duration of ischemia.
Upregulation of MMPs may be a common link between diabetes and ischemic stroke pathologies. Increased MMP-9 disrupts basal lamina and neurovascular unit structure promoting edema and HT in ischemic stroke [18, 19, [41] [42] [43] . MMP-9 knockout mice were shown to be protected against ischemic stroke. It is postulated that the HT complicating t-PA therapy is mediated through upregulation of MMP-9 [44] . We investigated the pattern of MMP-9 activity in cerebral macrovessels in diabetes and HG. While upregulation of MMP-9 in diabetes may contribute to greater HT in this group as evidenced by a significant reduction in MMP-9 activity and a parallel decrease in HT severity in metformin-treated GK rats, there was no difference in MMP-9 activity levels between control and control + HG group suggesting that other proteases may be involved in acute HG. It is also possible that there are differences at the microvascular level which we did not measure.
Our study assessed neurological function at 24 h while the damage is still evolving. The finding that the deficit is greater in the diabetic vs control groups and that HG exacerbated the neurological deficit in both control and diabetic rats suggests that both acute hyperglycemia and diabetes are critical for stroke outcome. An interesting finding is that while glycemic control with metformin did not affect infarct size (Fig. 2b) , it improved neurological outcome in diabetes (Fig. 5) . Pretreatment with metformin also reduced the deficit mediated by HG in diabetic rats. A novel aspect of the current study is that the functional outcome was worse in both acute and chronic hyperglycemia despite relatively smaller infarct sizes suggesting that vascular injury and potentially subsequent vascular dysfunction in these groups may be as important as the neuronal injury in determining neurological deficit. However, it is recognized that short-term 24-h measurement is a limitation of the study and more sensitive methods and longer-term outcomes are needed for confirmation.
Conclusion
Therapeutic options for ischemic stroke patients are limited. Given that 40-50% of acute ischemic stroke patients present with admission HG, understanding the mechanisms of neurovascular injury in acute HG and diabetes is very important. Since human stroke is extremely complex, preclinical studies need to be duplicated in different models of hyperglycemia to guide the clinical studies to develop better prevention and intervention strategies in the management of acute ischemic stroke. The current study advances the field by providing novel information on the effects of mild/moderate hyperglycemia in otherwise healthy animals as well as rats with preexisting diabetes and insulin resistance.
